Patent application number | Description | Published |
20090123415 | DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1 AUTOANTIBODIES - Methods of detecting individuals at risk for atherosclerosis and related vascular diseases involving the detection of IL-1α autoantibodies, as well as therapeutic methods to prevent or treat atherosclerosis and related vascular disease by administering a pharmaceutical composition comprising IL-1α autoantibodies. | 05-14-2009 |
20090191149 | IL-1alpha IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS - Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment. | 07-30-2009 |
20090298096 | Interleukin-1 alpha ABS and methods of use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 12-03-2009 |
20100040574 | TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES - Treating a patient with anti-IL-1α antibody or anti-IL-1α immunization as a cancer treatment. | 02-18-2010 |
20100068212 | Targeting pathogenic monocytes - The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality. | 03-18-2010 |
20110008282 | IL-1alpha immunization induces autoantibodies protective against atherosclerosis - Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment. | 01-13-2011 |
20110070229 | Method of selecting a monoclonal antibody for administration - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 03-24-2011 |
20110070230 | Method and devices for identifying and treating a subject who has developed an anti-antibody response - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 03-24-2011 |
20110071054 | Panel of monoclonal antibody containing pharmaceutical compositions - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 03-24-2011 |
20110071276 | Method of modifying a monoclonal antibody - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 03-24-2011 |
20110311547 | Arthritis Treatment - Administration of a monoclonal Ab (mAb) that specifically targets IL-1α is useful to treating articular and extra-articular symptoms of arthritis. | 12-22-2011 |
20120014971 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 01-19-2012 |
20120015384 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 01-19-2012 |
20120015433 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 01-19-2012 |
20120021512 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 01-26-2012 |
20120045444 | Treatment for Neoplastic Diseases - Administration of a mAb that specifically binds IL-1α is useful for treating tumor-associated diseases in human subjects. | 02-23-2012 |
20120094301 | Characterizing an allotypic phenotype of a subject - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 04-19-2012 |
20120094395 | Methods for identifying a subject who has developed an anti-antibody response - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 04-19-2012 |
20120114598 | IL-1alpha immunization induces autoantibodies protective against atherosclerosis - Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment. | 05-10-2012 |
20120164665 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 06-28-2012 |
20120231012 | Diagnosis, treatment, and prevention of vascular disorders using interleukin-1 autoantibodies - Method of detecting individuals at risk for atherosclerosis and related vascular diseases involving the detection of IL-1α autoantibodies, as well as therapeutic methods to prevent or treat atherosclerosis and related vascular disease by administering a pharmaceutical composition comprising IL-1α autantibodies. | 09-13-2012 |
20120251548 | Treatment of Dermatological Pathologies - Skin inflammation in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. | 10-04-2012 |
20120276110 | Modulation of Pathogenic Monocytes - The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality. | 11-01-2012 |
20130018173 | Identifying Affinity-Matured Human Antibodies - Antigen-specific immunoglobulin V-regions are identified from a library of nucleic acids amplified using polymerase chain reaction using leader sequence-specific forward primers. The use of leader sequence primers allows all V-region sequences to be amplified (including those with extensive 5′ end mutations) without loss of the original 5′ V gene segment sequence. A second V-region library is made using a larger than conventional set of 5′ V-region primers. The sequence errors introduced into the amplification products by this method are corrected using sequence information obtained in the products amplified by the V-region primers to screen the library created using the leader sequence primers. Amino acid sequence information from fragments of donor immunoglobulins can be used to assist in the identification of nucleic acids encoding the heavy and light chains of donor antibodies as well as to design primers to amplify such nucleic acids. | 01-17-2013 |
20130039921 | Treatment of Inflammatory Skin Disease and Psychiatric Conditions - The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. Anxiety and other psychiatric conditions are also improved with this treatment. | 02-14-2013 |
20130078258 | Cachexia Treatment - Administration of an antibody that specifically binds IL-1α is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia. | 03-28-2013 |
20130171728 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 07-04-2013 |
20130177982 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 07-11-2013 |
20130195877 | TREATMENT OF CACHEXIA BY TARGETING INTERLEUKIN-1 BETA - Administration of a mAb that specifically binds IL-1β is used for treating cachexia in human subjects. | 08-01-2013 |
20130287788 | Treatment of Psychiatric Conditions - The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. Anxiety and other psychiatric conditions are also improved with this treatment. | 10-31-2013 |
20140086933 | Treatment of Diabetes - Glycated hemoglobin (HbA1c) levels and other characteristics of diabetes are reduced by administering to a human subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. | 03-27-2014 |
20140099321 | TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF - Administration of an antibody that specifically binds IL-1α is useful for reducing the chance or severity of a major adverse clinical event occurring in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel, and for reducing the chance of restenosis occurring (or increasing the time until restenosis occurs) in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel. | 04-10-2014 |
20140186943 | NUCLEIC ACIDS ENCODING A HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO IL-1a - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 07-03-2014 |